CDMO partnerships vs in-house manufacturing in advanced therapies

Manufacturing strategy is central to the success of cell and gene therapy development. Whether outsourcing to a CDMO or building internal capacity, each approach carries implications for cost, control, and scalability. This session examines decision frameworks and partnership models that help organizations choose the most effective path for their stage of growth and product portfolio.

Key takeaways

• Compare the advantages and limitations of CDMO partnerships versus in-house manufacturing.
• Identify key factors such as scalability, quality control, and cost efficiency in decision-making.
• Explore hybrid approaches that balance flexibility with operational oversight.
• Discuss how early-stage planning influences long-term commercial and regulatory outcomes.
• Understand how collaboration and capacity building can optimize manufacturing resilience.